Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS

Journal of Endocrinology

Volumn 221, Issue 1, 2014, Pages

  van Bloemendaal, L ^a   ten Kulve, J S ^a   La Fleur, S E ^b   Ijzerman, R G ^a   Diamant, M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

CNS; Feeding behaviour; Glucagon like peptide 1; Obesity; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE;

APPETITE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CENTRAL NERVOUS SYSTEM; ENERGY BALANCE; ENERGY EXPENDITURE; FEEDING BEHAVIOR; FOOD INTAKE; FUNCTIONAL NEUROIMAGING; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL STIMULATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGULATORY MECHANISM; SATIETY; STOMACH DISTENSION; STOMACH EMPTYING; VAGUS NERVE; WEIGHT CHANGE; WEIGHT REDUCTION;

CNS; FEEDING BEHAVIOUR; GLUCAGON-LIKE PEPTIDE 1; OBESITY; TYPE 2 DIABETES;

ANIMALS; APPETITE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS;

EID: 84897895162     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0414     Document Type: Article

References (140)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA & Bloom SR 2005 The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem- hypothalamic pathway. Brain Research 1044 127-131
2. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, Sanz C, Vazquez P, Maldonado A, de Cáceres J et al. 2005 The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Journal of Neurochemistry 92 798-806
3. Anderson JW, Konz EC, Frederich RC & Wood CL 2001 Long-term weightloss maintenance: a meta-analysis of US studies. American Journal of Clinical Nutrition 74 579-584.
4. Anthony K, Reed LJ, Dunn JT, Bingham E, Hopkins D, Marsden PK & Amiel SA 2006 Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes 55 2986-2992
5. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF & Lean ME 2009 Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374 1606-1616
6. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean M, Niskanen L, Rasmussen M, Rissanen A, Rossner S et al. 2012 Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity 36 843-854
7. Baggio LL & Drucker DJ 2004 Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. Best Practice & Research. Clinical Endocrinology & Metabolism 18 531-554
8. Baggio LL, Huang Q, Brown TJ & Drucker DJ 2004a A recombinant human glucagon-like peptide (GLP)-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 2492-2500
9. Baggio LL, Huang Q, Brown TJ & Drucker DJ 2004b Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 546-558.
10. Bailey EF 2008 A tasty morsel: the role of the dorsal vagal complex in the regulation of food intake and swallowing. Focus on "BDNF/TrkB signaling interacts with GABAergic system to inhibit rhythmic swallowing in the rat," by Bariohay et al. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 295 R1048-R1049.
11. Barnett AH 2011 Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evidence 6 67-79.
12. Benedict C, Kern W, Schultes B, Born J & Hallschmid M 2008 Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. Journal of Clinical Endocrinology and Metabolism 93 1339-1344.)
13. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T & Roberts V 2009 Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current Medical Research and Opinion 25 65-75
14. Berthoud HR 2011 Metabolic and hedonic drives in the neural control of appetite: who is the boss? Current Opinion in Neurobiology 21 888-896
15. Bolli G, Munteanu M, Dotsenko S, Niemoeller E, Boka G & Hanefeld M 2011 Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1). Diabetologia 54 S316.
16. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M & Schoeller DA 2012 Alterations in energy balance following exenatide administration. Applied Physiology, Nutrition, and Metabolism 37 893-899.)
17. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, KroneW,Muller-Wieland D&KahnCR 2000 Role of braininsulin receptor in control of body weight and reproduction. Science 289 2122-2125.
18. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U et al. 2009 One-year treatment with exenatide improves b-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32 762-768.
19. Bunck MC, Diamant M, Eliasson B, Corner A, Shaginian RM, Heine RJ, TaskinenMR,Yki-JarvinenH&SmithU2010 Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33 1734-1737.
20. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H & Diamant M 2011 Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34 2041-2047.
21. Buse JB, Henry RR, Han J, Kim DD, Fineman MS & Baron AD 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 2628-2635.
22. Buse JB, Rosenstock J, Sesti G, SchmidtWE, Montanya E, Brett JH, ZychmaM & Blonde L 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 39-47.
23. ChaudhriOB,ParkinsonJR,KuoYT,DruceMR,HerlihyAH,Bell JD,DhilloWS, Stanley SA, Ghatei MA & Bloom SR 2006 Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin inmice detected bymanganese-enhancedmagneticresonance imaging. Biochemical and Biophysical Research Communications 350 298-306.
24. Chelikani PK, Haver AC & Reidelberger RD 2005 Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 288 R1695-R1706.
25. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P & Friedman JM 2001 Selective deletion of leptin receptor in neurons leads to obesity. Journal of Clinical Investigation 108 1113-1121.
26. ConsidineRV,SinhaMK,HeimanML, KriauciunasA, StephensTW,NyceMR, Ohannesian JP, Marco CC, McKee LJ & Bauer TL 1996 Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New England Journal of Medicine 334 292-295.
27. Costantini VJ, Vicentini E, Sabbatini FM, Valerio E, Lepore S, Tessari M, Sartori M, Michielin F, Melotto S, Bifone A et al. 2011 GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs. Neuroendocrinology 94 158-168.
28. Crawley JN & Beinfeld MC 1983 Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302 703-706.
29. Cummings BP 2013 Leptin therapy in type 2 diabetes. Diabetes, Obesity & Metabolism 15 607-612.
30. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C & Kilcoyne A 2009 Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity & Metabolism 11 1153-1162.
31. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS & Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 1092-1100.
32. DeSilva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, Bloom SR, Matthews PM, Beaver JD et al. 2011 The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans. Cell Metabolism 14 700-706.
33. DiamantM,VanGaal L, Stranks S,NorthrupJ,CaoD,TaylorK&TrautmannM 2010 Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375 2234-2243.
34. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H & Skibicka KP 2012 The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. Journal of Neuroscience 32 4812-4820.
35. Dossat AM, Lilly N, Kay K & Williams DL 2011 Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. Journal of Neuroscience 31 14453-14457.
36. Drucker DJ 2006 The biology of incretin hormones. Cell Metabolism 3 153-165.
37. Drucker DJ & NauckMA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 1696-1705.
38. Drucker DJ, Philippe J, Mojsov S, Chick WL & Habener JF 1987 Glucagonlike peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. PNAS 84 3434-3438.
39. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D & Porter L 2008 Exenatide once weekly versus twice daily for thetreatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372 1240-1250.
40. DuringMJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ et al. 2003 Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine 9 1173-1179.
41. EnrioriPJ,EvansAE, Sinnayah P, Jobst EE, Tonelli-LemosL,Billes SK, GlavasMM, Grayson BE, Perello M, Nillni EA et al. 2007 Diet-induced obesity causes severe but reversible leptin resistance in arcuatemelanocortin neurons. Cell Metabolism 5 181-194.
42. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E & Colditz GA 2001 Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Archives of Internal Medicine 161 1581-1586.
43. Fineman MS, Cirincione BB, Maggs D & Diamant M 2012 GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity & Metabolism 14 675-688.
44. Flegal KM, Carroll MD, Kit BK & Ogden CL 2012 Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. Journal of the American Medical Association 307 491-497.
45. Flint A, Raben A, Astrup A & Holst JJ 1998 Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation 101 515-520.
46. Flint A, Raben A, Rehfeld JF, Holst JJ & Astrup A 2000 The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. International Journal of Obesity and Related Metabolic Disorders 24 288-298.
47. Flint A, Raben A, Ersboll AK, Holst JJ & Astrup A 2001 The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity and Related Metabolic Disorders 25 781-792.
48. Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T & Yoshimatsu H 2012 Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. Journal of Neurochemistry 121 66-76.
49. Gallwitz B, Bohmer M, Segiet T, Molle A, Milek K, Becker B, Helsberg K, Petto H, Peters N & Bachmann O 2011 Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 34 604-606.
50. Gao Q & Horvath TL 2008 Neuronal control of energy homeostasis. FEBS Letters 582 132-141.
51. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M & Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 473-481.
52. Garber A, Henry RR, Ratner R, Hale P, Chang CT & Bode B 2011 Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes, Obesity & Metabolism 13 348-356.
53. van Genugten RE, van Raalte DH & Diamant M 2009 Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide Diabetes Research and Clinical Practice 86(Suppl 1) S26-S34
54. Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C & Heilig JS 2013 Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. Journal of Comparative Neurology 521 2235-2261.
55. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J & Beglinger C 1999 Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. American Journal of Physiology 276 R1541-R1544.
56. Harder H, Nielsen L, Tu DT & Astrup A 2004 The effect of liraglutide, a longacting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 27 1915-1921.
57. Havel PJ 2001 Peripheral signals conveying metabolic information to the brain: short-term and long-term regulation of food intake and energy homeostasis. Experimental Biology and Medicine 226 963-977.
58. Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W & Grill HJ 2011 The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 301 R1479-R1485.
59. Heine RJ, Van Gaal LF, Johns D,MihmMJ, WidelMH & Brodows RG 2005 Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Annals of Internal Medicine 143 559-569.
60. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiological Reviews 87 1409-1439.
61. Holst JJ & Deacon CF 2005 Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48 612-615.
62. Holz GG, KuhtreiberWM& Habener JF 1993 Pancreatic b-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361 362-365.
63. HorowitzM, Flint A, Jones KL, Hindsberger C, Rasmussen MF, Kapitza C, Doran S, Jax T, ZdravkovicM&ChapmanIM 2012 Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying intype 2 diabetes. Diabetes Research and Clinical Practice 97 258-266.
64. Hwa JJ, Ghibaudi L, Williams P, Witten MB, Tedesco R & Strader CD 1998 Differential effects of intracerebroventricular glucagon-like peptide-1 on feeding and energy expenditure regulation. Peptides 19 869-875.
65. Janssen P, Vanden BP, Verschueren S, Lehmann A, Depoortere I & Tack J 2011 Review article: The role of gastric motility in the control of food intake. Alimentary Pharmacology & Therapeutics 33 880-894.
66. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M & Knudsen LB 2012 Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes, Obesity & Metabolism 14 531-538.
67. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, ZdravkovicM, Strauss BJ & Garber AJ 2009 Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes, Obesity & Metabolism 11 1163-1172.
68. Jordan J, Greenway FL, Leiter LA, Li Z, Jacobson P, Murphy K, Hill J, Kler L & AftringRP 2008Stimulationof cholecystokinin-A receptorswithGI181771X does not cause weight loss in overweight or obese patients. Clinical Pharmacology and Therapeutics 83 281-287.
69. Kastin AJ, Akerstrom V & Pan W 2002 Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. Journal of Molecular Neuroscience 18 7-14.
70. Kendall DM,RiddleMC,Rosenstock J, Zhuang D, KimDD, FinemanMS& BaronAD 2005Effectsof exenatide (exendin-4)onglycemiccontrol over 30 weeks in patients with type 2 diabetes treated withmetformin and a sulfonylurea. DiabetesCare 28 1083-1091.
71. Kenny PJ 2011 Reward mechanisms in obesity: new insights and future directions. Neuron 69 664-679.
72. Kieffer TJ, McIntosh CH & Pederson RA 1995 Degradation of glucosedependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 3585-3596.
73. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E et al. 2008 Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149 4768-4777.
74. Knudsen LB,Nielsen PF,Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H,WilkenM& Agerso H 2000 Potent derivatives of glucagonlike peptide-1 with pharmacokinetic properties suitable for once daily administration. Journal of Medicinal Chemistry 43 1664-1669.
75. Kreymann B, Williams G, Ghatei MA & Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2 1300-1304.
76. Larsen PJ, Tang-Christensen M, Holst JJ & Orskov C 1997 Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77 257-270.
77. Levin BE & Dunn-Meynell AA 2002 Reduced central leptin sensitivity in rats with diet-induced obesity. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 283 R941-R948.
78. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K et al. 2009 GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. PNAS 106 1285-1290.
79. Little TJ, Pilichiewicz AN, Russo A, Phillips L, Jones KL, NauckMA,Wishart J, HorowitzM & Feinle-Bisset C 2006 Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. Journal of Clinical Endocrinology and Metabolism 91 1916-1923.
80. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, Ananthakrishnan G, Rohner-Jeanrenaud F, Drucker DJ, DiMarchi R et al. 2012 Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 61 2753-2762.
81. Lutter M & Nestler EJ 2009 Homeostatic and hedonic signals interact in the regulation of food intake. Journal of Nutrition 139 629-632.
82. Macconell L, Pencek R, Li Y, Maggs D & Porter L 2013 Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 6 31-41.
83. Marathe CS, Rayner CK, Jones KL & Horowitz M 2011 Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Experimental Diabetes Research 2011 279-530.
84. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD & Colagiuri S 2009 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine 26 268-278.
85. McClean PL, Parthsarathy V, Faivre E & Holscher C 2011 The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. Journal of Neuroscience 31 6587-6594.
86. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE & Nauck MA 2003Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88 2719-2725.
87. Merchenthaler I, Lane M & Shughrue P 1999 Distribution of pre-proglucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. Journal of Comparative Neurology 403 261-280.
88. Min DK, Tuor UI, Koopmans HS & Chelikani PK 2011 Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals. Gastroenterology 141 1832-1841.
89. Mithieux G 2013 Nutrient control of hunger by extrinsic gastrointestinal neurons. Trends in Endocrinology and Metabolism 24 378-384.
90. Mojsov S, Weir GC & Habener JF 1987 Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. Journal of Clinical Investigation 79 616-619.
91. Moon HS, Chamberland JP, Diakopoulos KN, Fiorenza CG, Ziemke F, Schneider B & Mantzoros CS 2011 Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans. Diabetes Care 34 132-138.
92. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM & Brodows RG 2008 Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallelgroup study. Clinical Therapeutics 30 1448-1460.
93. Naslund E, Gutniak M, Skogar S, Rossner S & Hellstrom PM 1998 Glucagonlike peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. American Journal of Clinical Nutrition 68 525-530.
94. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R & Schmiegel WH 1997 Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology 273 E981-E988.
95. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R & TrautmannM 2007 A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50 259-267.
96. NauckM, FridA,Hermansen K, ShahNS, Tankova T, Mitha IH, ZdravkovicM, DuringM& Matthews DR 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32 84-90.
97. Nauck MA, Kemmeries G, Holst JJ & Meier JJ 2011 Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60 1561-1565.
98. Nielsen LL, Young AA & Parkes DG 2004 Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory Peptides 117 77-88.
99. Osaka T, Endo M, Yamakawa M & Inoue S 2005 Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26 1623-1631.
100. Pannacciulli N, Le DS, Salbe AD, Chen K, Reiman EM, Tataranni PA & Krakoff J 2007 Postprandial glucagon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. NeuroImage 35 511-517.
101. Petersen AB & Christensen M 2013 Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes, MetabolicSyndrome and Obesity: Targets and Therapy 6 217-231.
102. Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H & Aronson R 2013 Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes, Obesity & Metabolism 15 1000-1007.
103. Plamboeck A, Veedfald S, Deacon CF, Hartmann B,Wettergren A, Svendsen LB, Meisner S, Hovendahl C, Vilsboll T, Knop FK et al. 2013 The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. American Journal of Physiology. Gastrointestinal and Liver Physiology 304 G1117-G1127.
104. Polonsky KS, Given BD & Van Cauter E 1988 Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. Journal of Clinical Investigation 81 442-448.
105. RaufmanJP, Singh L, SinghG&Eng J 1992 Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. Journal of Biological Chemistry 267 21432-21437.
106. Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, Ping L & Rosenstock J 2013 Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. Rodriquez de Fonseca F, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J & Blazquez E 2000 Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 49 709- 717.
107. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K & Trautmann M 2010 Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 33 1173-1175.
108. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, ZdravkovicM, Ravn GM& Simo R 2009 Liraglutide vs insulin glargine and placebo in combinationwithmetformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5metCSU): a randomisedcontrolled trial. Diabetologia52 2046-2055.
109. Ruttimann EB, Arnold M, Hillebrand JJ, Geary N & LanghansW 2009 Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150 1174-1181.
110. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA & Seeley RJ 2008 Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57 2046-2054.
111. Schick RR, Zimmermann JP, vorm Walde T & Schusdziarra V 2003 Peptides that regulate food intake: glucagon-like peptide 1-(7-36) amide acts at lateral and medial hypothalamic sites to suppress feeding in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 284 R1427-R1435.
112. Schirra J,WankU, Arnold R,GokeB&KatschinskiM 2002 Effects of glucagonlike peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 50 341-348.
113. Schlogl H, Kabisch S, Horstmann A, Lohmann G, Muller K, Lepsien J, Busse-Voigt F, Kratzsch J, Pleger B, Villringer A et al. 2013 Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diabetes Care 36 1933-1940.
114. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ & Baskin DG 2000 Central nervous system control of food intake. Nature 404 661-671.
115. Scott KA & Moran TH 2007 The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 293 R983-R987.
116. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL & Drucker DJ 1996 Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2 1254-1258.
117. Seino Y, Min KW, Niemoeller E & Takami A 2012 Randomized, doubleblind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes, Obesity & Metabolism 14 910-917.
118. Shugrue PJ, Lane M & Merchenthaler I 1996 Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137 5159-5162.
119. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N & Snaith A 2011 Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 10 CD006423.
120. Sivertsen J, Rosenmeier J, Holst JJ & Vilsboll T 2012 The effect of glucagonlike peptide 1 on cardiovascular risk. Nature Reviews. Cardiology 9 209-222.
121. Stratton IM, Adler AI,NeilHA, Matthews DR,Manley SE, Cull CA,HaddenD, Turner RC & Holman RR 2000 Association of glycaemia with macrovascular andmicrovascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 405-412.
122. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH & Egan JM 2000 Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 1936-1941.
123. Talsania T, Anini Y, Siu S, Drucker DJ & Brubaker PL 2005 Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146 3748-3756.
124. Toft-Nielsen MB, Madsbad S & Holst JJ 1999 Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22 1137-1143.
125. Trinko R, Sears RM, Guarnieri DJ & DiLeone RJ 2007 Neural mechanisms underlying obesity and drug addiction. Physiology & Behavior 91 499-505.
126. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD et al. 1996 A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379 69-72.
127. Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, Perez E, Miller J, Hoffer BJ, Greig NH et al. 2013 Exendin-4, a glucagonlike peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Experimental Neurology 239 170-182.
128. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP et al. 2007 Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148 4965-4973.
129. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ & Astrup A 2001 A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. Journal of Clinical Endocrinology and Metabolism 86 4382-4389.
130. Vilsboll T & Garber AJ 2012 Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes, Obesity & Metabolism 14(Suppl 2) 41-49.
131. Vilsboll T, Christensen M, Junker AE, Knop FK & Gluud LL 2012 Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematicreview and meta-analyses of randomised controlled trials. BMJ 344 d7771.
132. Volkow ND & Wise RA 2005 How can drug addiction help us understand obesity? Nature Neuroscience 8 555-560
133. Wang GJ, Volkow ND, Thanos PK & Fowler JS 2004 Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. Journal of Addictive Diseases 23 39-53
134. WernerU,HaschkeG,HerlingAW&KramerW 2010Pharmacologicalprofileof lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory Peptides 164 58-64.
135. Whiting DR, Guariguata L,Weil C & Shaw J 2011 IDF diabetes atlas: global estimatesof theprevalence ofdiabetes for 2011and2030. Diabetes Research and Clinical Practice 94 311-321.
136. Williams DL, Baskin DG & Schwartz MW 2009 Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150 1680-1687.
137. Woods SC, Lotter EC, McKay LD & Porte D Jr 1979 Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 282 503-505.
138. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B & Denaro M 1999 Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48 1026-1034
139. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S & Holst JJ 2001 Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 24 720-725
140. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, ZdravkovicM&BlondeL 2009Efficacy andsafetyof thehumanglucagonlike peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 MetCTZD). Diabetes Care 32 1224-1230